newsfilter
← Latest News
PR Newswire·

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpointConsistent with prior studies, VQW-765 was safe and well toleratedWASHINGTON, Oct. 14, 2026 /PRNewswire/ --